YILIMART - MSC Phenotyping Kit, human

The MSC Phenotyping Kit was developed for the fast and standardized characterization and quantification of cultured human MSCs by flow cytometry based on the defined ISCT standards

¹

.

The MSC Phenotyping Kit applies recombinant engineered REAfinity™ antibodies, and contains

A 5-color antibody cocktail including positive markers (CD73, CD90, CD105) and negative markers (CD34, CD45, CD14, CD19, and anti-HLA-DR)
A 5-color antibody cocktail for isotype control
Individual single color fluorochrome-conjugated antibodies for compensation control

Background information

Human mesenchymal stem cells or stromal cells (MSCs) hold great promise for regenerative applications like bone- and cartilage repair, as well as for immunomodulatory applications. However, MSCs can be isolated from a variety of tissues, expanded under different conditions, and characterized with regard to differentiation potential as well as cell surface marker expression.

Minimal criteria for a common definition of human MSCs were defined by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) to facilitate a better comparability of data amongst investigators, accelerating new scientific discoveries, and facilitating the development of novel cellular therapies.¹ The committee proposed that MSCs should be plastic adherent when maintained under standard culture conditions. Also MSCs should differentiate to osteoblasts, adipocytes, and chondrocytes under standard

in vitro

differentiating conditions. When measured by flow cytometry, ≥95% of the MSC population must express CD73, CD90, and CD105, and these cells must lack expression (≤2% positive) of CD34, CD45, CD11b or CD14, CD19 or CD79α, and HLA-DR.

Figure 1

Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant

^®

Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.

Selected references
1. Dominici, M. et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317

查看数据文件查看下载

MSC Phenotyping Kit, human

For research use only

您浏览过的商品

Background information

Figure 1

Selected references

相关产品